Search for content, post, videos

AZ announces positive results from phase III programme

sean_bohen_AZ
Benralizumab, AZ's potential new medicine and anti-eosinophil monoclonal antibody, has been well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials. This demonstrates significant reductions in the annual asthma exacerbation rate compared to placebo.
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.